Abbisko readies pan-KRAS inhibitor ABSK211 for China Phase 1 in tumors
Abbisko Therapeutics registered a Phase 1 dose-finding trial of ABSK211 in KRAS-altered tumors, entering a China-heavy field already carrying more than two dozen active KRAS-directed programs.
Executive Summary
- Abbisko Therapeutics registered a Phase 1 dose-escalation study of its oral pan-KRAS inhibitor in patients with advanced tumors carrying a KRAS alteration, with sites set to open in China this fall.
- The trial enters a KRAS-targeted landscape that already includes dozens of active programs spanning allele-specific inhibitors with regulatory approvals elsewhere and earlier pan-RAS candidates in later-stage testing, making differentiation on selectivity and tolerability the central question rather than novelty of target.
- Because two prior KRAS x tumor Phase 1 programs from other sponsors have already been terminated, the study's safety and dose-finding readout will be measured against a class that has shown a real failure rate at this exact stage.
- Abbisko brings a completed track record across its broader pipeline into this new program, which sets a baseline for execution even though it says nothing about whether ABSK211 itself will clear the clinic.
The trial
The study, filed as NCT07718165, will enroll an anticipated 247 patients with histologically confirmed, locally advanced or metastatic tumors harboring a KRAS alteration who have received at least one prior systemic therapy. It is designed as an open-label, single-arm dose-escalation and expansion study run at sites in China, with a primary completion date set for December 30, 2029, and full study completion targeted for June 30, 2030. The trial is not registered as registrational, positioning it as an early clinical-pharmacology and safety study rather than a pivotal readout. NCT07718165A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS AlterationNCT07718165
What the trial measures
The registered primary endpoints are adverse events, dose-limiting toxicities assessed from the dosing run-in through Day 21, and serious adverse events tracked from consent through 30 days after the last dose, the standard safety and tolerability battery for a first-in-human dose-finding study. Secondary endpoints cover pharmacokinetic measures including maximum concentration, half-life, and area under the concentration-time curve, alongside exploratory efficacy signals: objective response rate, disease control rate, duration of response, and progression-free and overall survival tracked through 24 months. The design excludes patients previously treated with any KRAS-, pan-KRAS-, or pan-RAS-directed inhibitor, meaning any early activity signal will come from a RAS-inhibitor-naive population. NCT07718165A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS AlterationNCT07718165
The competitive field
ABSK211 enters a target class that is not novel: 17 trials across 14 sponsors have already tested KRAS-directed therapies in tumors, with the most advanced reaching Phase 3, including Revolution Medicines' daraxonrasib, the closest direct comparator by target and modality, now in a Phase 3 pancreatic ductal adenocarcinoma trial. Allele-specific KRAS G12C inhibitors adagrasib and sotorasib are already approved, but for KRAS G12C-mutated non-small cell lung cancer and colorectal cancer specifically, not for the broader KRAS-altered -tumor population this trial targets. Other direct comparators in earlier-stage testing include Jacobio Pharmaceuticals' JAB-23E73 and Blueprint Medicines' BLU-924, both in Phase 1/2 pancreatic programs, alongside Servier's BDTX-4933 in non-small cell lung cancer.
The historical bar
Among Phase 1 trials pairing KRAS with tumors, three of five resolved programs completed and two terminated, a 40% termination rate across a small but real sample of prior attempts at this exact stage. Two distinct sponsors have failed in this specific target-indication pairing, establishing that dose-finding attrition, not just competitive crowding, is a documented feature of this class. Against that backdrop, a completed dose-escalation with a defined maximum tolerated or recommended Phase 2 dose, rather than early termination for toxicity, would be the signal that ABSK211 clears the bar this specific trial-stage history has set.
Sponsor and timing
Abbisko has completed all 12 of its previously tracked trials globally with none terminated, and currently runs 37 trials across its pipeline in various stages including 11 recruiting and 5 not yet recruiting. The registration shows no protocol amendments beyond its initial filing and carries a stable registry-churn profile, consistent with a newly filed study that has not yet begun enrolling. Enrollment is anticipated rather than actual, and the trial has not yet opened for recruitment as of this filing. NCT07718165A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS AlterationNCT07718165
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.